AbbVie results beat expectations despite low-cost competition to blockbuster Humira
October 27, 2023 at 07:42 AM EDT
Drugmaker raises its full-year earnings outlook, boosts 2024 dividend 4.7%
|
||||||||||||
|
||||||||||||
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map |